Trial results of venetoclax plus CHOP therapy with rituximab or obinutuzumab in non-Hodgkin lymphoma
Andrew Zelenetz
• 3 Dec 2016
Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York City, NY discusses the results of a Phase Ib trial of venetoclax plus CHOP therapy with rituximab or obinutuzumab in non-Hodgkin lymphoma patients (NCT02055820). Prof. Zelenetz explains its mechanism of action and why, as a single agent, it has had relatively limited effects on some of the B-cell lymphomas. The trial presented at ASH asked the question of how venetoclax can be combined with standard treatment. Prof. Zelenetz then summarizes the main findings of this trial. Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA
